ID   NL1A1_RAT               Reviewed;        1218 AA.
AC   D9I2F9; A0A0G2QC28; F1LPA5;
DT   02-JUN-2021, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 1.
DT   02-OCT-2024, entry version 95.
DE   RecName: Full=NACHT, LRR and PYD domains-containing protein 1a allele 1 {ECO:0000305};
DE            EC=3.4.-.- {ECO:0000250|UniProtKB:Q9C000};
DE   Contains:
DE     RecName: Full=NACHT, LRR and PYD domains-containing protein 1a, C-terminus {ECO:0000305};
DE              Short=Nlrp1a-CT {ECO:0000250|UniProtKB:Q9C000};
DE   Contains:
DE     RecName: Full=NACHT, LRR and PYD domains-containing protein 1a, N-terminus {ECO:0000305};
DE              Short=Nlrp1a-NT {ECO:0000250|UniProtKB:Q9C000};
GN   Name=Nlrp1a {ECO:0000312|RGD:1310963};
GN   Synonyms=Nlrp1 {ECO:0000303|PubMed:20502689};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, ACTIVITY REGULATION, AND PROTEOLYTIC
RP   CLEAVAGE BY ANTHRAX LETHAL TOXIN.
RC   STRAIN=BN-lx {ECO:0000312|EMBL:ADI96226.1},
RC   Brown Norway {ECO:0000312|EMBL:ADI96225.1},
RC   Dahl salt-sensitive {ECO:0000312|EMBL:ADI96228.1},
RC   Sprague-Dawley {ECO:0000312|EMBL:ADI96231.1}, and
RC   Wistar {ECO:0000312|EMBL:ADI96234.1};
RX   PubMed=20502689; DOI=10.1371/journal.ppat.1000906;
RA   Newman Z.L., Printz M.P., Liu S., Crown D., Breen L., Miller-Randolph S.,
RA   Flodman P., Leppla S.H., Moayeri M.;
RT   "Susceptibility to anthrax lethal toxin-induced rat death is controlled by
RT   a single chromosome 10 locus that includes rNlrp1.";
RL   PLoS Pathog. 6:e1000906-e1000906(2010).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [3]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=31383852; DOI=10.1038/s41419-019-1817-5;
RA   Gai K., Okondo M.C., Rao S.D., Chui A.J., Ball D.P., Johnson D.C.,
RA   Bachovchin D.A.;
RT   "DPP8/9 inhibitors are universal activators of functional NLRP1 alleles.";
RL   Cell Death Dis. 10:587-587(2019).
RN   [4]
RP   REVIEW.
RX   PubMed=32558991; DOI=10.1111/imr.12884;
RA   Taabazuing C.Y., Griswold A.R., Bachovchin D.A.;
RT   "The NLRP1 and CARD8 inflammasomes.";
RL   Immunol. Rev. 297:13-25(2020).
RN   [5] {ECO:0007744|PDB:7CRV, ECO:0007744|PDB:7CRW}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 783-968 AND 969-1122 IN COMPLEX
RP   WITH DPP9, FUNCTION, PROTEOLYTIC CLEAVAGE, ACTIVITY REGULATION, AND
RP   MUTAGENESIS OF HIS-942 AND SER-969.
RX   PubMed=33731929; DOI=10.1038/s41586-021-03320-w;
RA   Huang M., Zhang X., Toh G.A., Gong Q., Wang J., Han Z., Wu B., Zhong F.,
RA   Chai J.;
RT   "Structural and biochemical mechanisms of NLRP1 inhibition by DPP9.";
RL   Nature 592:773-777(2021).
CC   -!- FUNCTION: Acts as the sensor component of the Nlrp1a inflammasome,
CC       which mediates inflammasome activation in response to various pathogen-
CC       associated signals, leading to subsequent pyroptosis (PubMed:33731929).
CC       Inflammasomes are supramolecular complexes that assemble in the cytosol
CC       in response to pathogens and other damage-associated signals and play
CC       critical roles in innate immunity and inflammation (By similarity).
CC       Acts as a recognition receptor (PRR): recognizes specific pathogens and
CC       other damage-associated signals, such as B.anthracis lethal toxin (LT)
CC       or Val-boroPro inhibitor, and mediates the formation of the
CC       inflammasome polymeric complex (PubMed:20502689, PubMed:31383852,
CC       PubMed:33731929). In response to pathogen-associated signals, the N-
CC       terminal part of Nlrp1a is degraded by the proteasome, releasing the
CC       cleaved C-terminal part of the protein (NACHT, LRR and PYD domains-
CC       containing protein 1a, C-terminus), which polymerizes to initiate the
CC       formation of the inflammasome complex: the inflammasome directly
CC       recruits pro-caspase-1 (proCASP1) independently of PYCARD/ASC and
CC       promotes caspase-1 (CASP1) activation, which subsequently cleaves and
CC       activates inflammatory cytokines IL1B and IL18 and gasdermin-D (GSDMD),
CC       leading to pyroptosis (By similarity). In the absence of GSDMD
CC       expression, the Nlrp1a inflammasome is able to recruit and activate
CC       CASP8, leading to activation of gasdermin-E (GSDME) (By similarity).
CC       {ECO:0000250|UniProtKB:Q2LKU9, ECO:0000250|UniProtKB:Q2LKW6,
CC       ECO:0000250|UniProtKB:Q9C000, ECO:0000269|PubMed:20502689,
CC       ECO:0000269|PubMed:31383852, ECO:0000269|PubMed:33731929}.
CC   -!- FUNCTION: [NACHT, LRR and PYD domains-containing protein 1a allele 1]:
CC       Constitutes the precursor of the Nlrp1a inflammasome, which mediates
CC       autoproteolytic processing within the FIIND domain to generate the N-
CC       terminal and C-terminal parts, which are associated non-covalently in
CC       absence of pathogens and other damage-associated signals.
CC       {ECO:0000250|UniProtKB:Q9C000}.
CC   -!- FUNCTION: [NACHT, LRR and PYD domains-containing protein 1a, N-
CC       terminus]: Regulatory part that prevents formation of the Nlrp1a
CC       inflammasome: in absence of pathogens and other damage-associated
CC       signals, interacts with the C-terminal part of Nlrp1a (NACHT, LRR and
CC       PYD domains-containing protein 1a, C-terminus), preventing activation
CC       of the Nlrp1a inflammasome. In response to pathogen-associated signals,
CC       this part is ubiquitinated by the N-end rule pathway and degraded by
CC       the proteasome, releasing the cleaved C-terminal part of the protein,
CC       which polymerizes and forms the Nlrp1a inflammasome.
CC       {ECO:0000250|UniProtKB:Q9C000}.
CC   -!- FUNCTION: [NACHT, LRR and PYD domains-containing protein 1a, C-
CC       terminus]: Constitutes the active part of the Nlrp1a inflammasome
CC       (PubMed:33731929). In absence of pathogens and other damage-associated
CC       signals, interacts with the N-terminal part of Nlrp1a (NACHT, LRR and
CC       PYD domains-containing protein 1a, N-terminus), preventing activation
CC       of the Nlrp1a inflammasome. In response to pathogen-associated signals,
CC       the N-terminal part of Nlrp1a is degraded by the proteasome, releasing
CC       this form, which polymerizes to form the Nlrp1a inflammasome complex:
CC       the Nlrp1a inflammasome complex then directly recruits pro-caspase-1
CC       (proCASP1) and promotes caspase-1 (CASP1) activation, leading to
CC       gasdermin-D (GSDMD) cleavage and subsequent pyroptosis.
CC       {ECO:0000250|UniProtKB:Q9C000, ECO:0000269|PubMed:33731929}.
CC   -!- ACTIVITY REGULATION: Activated by cleavage by B.anthracis lethal toxin
CC       (LT) endopeptidase (PubMed:20502689). Cleavage by LT promotes
CC       ubiquitination and degradation of the N-terminal part, releasing the
CC       cleaved C-terminal part of the protein (NACHT, LRR and PYD domains-
CC       containing protein 1a, C-terminus), which polymerizes and forms the
CC       Nlrp1a inflammasome (By similarity). Nlrp1a inflammasome is inhibited
CC       by DPP8 and DPP9, which sequester the C-terminal fragment of Nlrp1a
CC       (NACHT, LRR and PYD domains-containing protein 1a, C-terminus) in a
CC       ternary complex, thereby preventing Nlrp1a oligomerization and
CC       activation (PubMed:33731929). Nlrp1a inflammasome is weakly activated
CC       by Val-boroPro (Talabostat, PT-100), an inhibitor of dipeptidyl
CC       peptidases DPP8 and DPP9 (PubMed:31383852). Val-boroPro relieves
CC       inhibition of DPP8 and/or DPP9 by promoting disruption of the ternary
CC       complex, releasing its C-terminal part from autoinhibition (By
CC       similarity). Weakly activated by Toxoplasma gondii (PubMed:31383852).
CC       {ECO:0000250|UniProtKB:Q2LKW6, ECO:0000250|UniProtKB:Q9C000,
CC       ECO:0000269|PubMed:20502689, ECO:0000269|PubMed:31383852,
CC       ECO:0000269|PubMed:33731929}.
CC   -!- SUBUNIT: Interacts (via LRR repeats) with BCL2 and BCL2L1 (via the loop
CC       between motifs BH4 and BH3) (By similarity). Interacts with NOD2; this
CC       interaction is enhanced in the presence of muramyl dipeptide (MDP) and
CC       increases IL1B release (By similarity). Interacts with EIF2AK2/PKR;
CC       this interaction requires EIF2AK2 activity, is accompanied by EIF2AK2
CC       autophosphorylation and promotes inflammasome assembly in response to
CC       danger-associated signals (By similarity). Interacts with MEFV; this
CC       interaction targets Nlrp1a to degradation by autophagy, hence
CC       preventing excessive IL1B- and IL18-mediated inflammation (By
CC       similarity). Interacts with DPP9; leading to inhibit activation of the
CC       inflammasome (PubMed:33731929). DPP9 acts via formation of a ternary
CC       complex, composed of a DPP9 homodimer, one full-length NLRP1 protein,
CC       and one cleaved C-terminus of Nlrp1a (NACHT, LRR and PYD domains-
CC       containing protein 1a, C-terminus) (PubMed:33731929). Interacts with
CC       DPP8; leading to inhibit activation of the inflammasome, probably via
CC       formation of a ternary complex with DPP8 (By similarity).
CC       {ECO:0000250|UniProtKB:Q9C000, ECO:0000269|PubMed:33731929}.
CC   -!- SUBUNIT: [NACHT, LRR and PYD domains-containing protein 1a, N-
CC       terminus]: Interacts with the C-terminal part of Nlrp1a (NACHT, LRR and
CC       PYD domains-containing protein 1a, C-terminus) in absence of pathogens
CC       and other damage-associated signals. {ECO:0000250|UniProtKB:Q9C000}.
CC   -!- SUBUNIT: [NACHT, LRR and PYD domains-containing protein 1a, C-
CC       terminus]: Interacts with the N-terminal part of Nlrp1a (NACHT, LRR and
CC       PYD domains-containing protein 1a, N-terminus) in absence of pathogens
CC       and other damage-associated signals (By similarity). Homomultimer;
CC       forms the Nlrp1a inflammasome polymeric complex, a filament composed of
CC       homopolymers of this form in response to pathogens and other damage-
CC       associated signals (By similarity). The Nlrp1a inflammasome polymeric
CC       complex directly recruits pro-caspase-1 (proCASP1) independently of
CC       PYCARD/ASC (By similarity). Interacts (via CARD domain) with CASP1 (via
CC       CARD domain); leading to CASP1 activation (By similarity).
CC       {ECO:0000250|UniProtKB:Q9C000}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000250|UniProtKB:Q9C000}. Cytoplasm
CC       {ECO:0000250|UniProtKB:Q9C000}. Nucleus {ECO:0000250|UniProtKB:Q9C000}.
CC   -!- SUBCELLULAR LOCATION: [NACHT, LRR and PYD domains-containing protein
CC       1a, C-terminus]: Inflammasome {ECO:0000250|UniProtKB:Q9C000}.
CC   -!- DOMAIN: The leucine-rich repeat (LRR) domain may be involved in
CC       autoinhibition in the absence of activating signal, possibly through
CC       intramolecular interaction with the NACHT domain.
CC       {ECO:0000250|UniProtKB:Q2LKW6}.
CC   -!- DOMAIN: The FIIND (domain with function to find) region is involved in
CC       homomerization, but not in CASP1-binding. Autocatalytic cleavage in
CC       this region occurs constitutively, prior to activation signals, and is
CC       required for inflammasome activity (IL1B release), possibly by
CC       facilitating CASP1 binding. Both N- and C-terminal fragments remain
CC       associated. {ECO:0000250|UniProtKB:Q2LKW6}.
CC   -!- DOMAIN: [NACHT, LRR and PYD domains-containing protein 1a, C-terminus]:
CC       The C-terminal part of Nlrp1a oligomerizes to form the core of the
CC       Nlrp1a inflammasome filament: in the filament, the CARD domains form a
CC       central helical filaments that are promoted by oligomerized, but
CC       flexibly linked, UPA regions surrounding the filaments. The UPA region
CC       reduces the threshold needed for filament formation and signaling.
CC       {ECO:0000250|UniProtKB:Q9C000}.
CC   -!- PTM: [NACHT, LRR and PYD domains-containing protein 1a allele 1]:
CC       Autocatalytically cleaved. Autocatalytic cleavage in FIIND region
CC       occurs constitutively, prior to activation signals, and is required for
CC       inflammasome activity (IL1B release), possibly by facilitating CASP1
CC       binding. Both N- and C-terminal parts remain associated non-covalently.
CC       {ECO:0000250|UniProtKB:Q9C000}.
CC   -!- PTM: [NACHT, LRR and PYD domains-containing protein 1a, N-terminus]:
CC       (Microbial infection) Cleavage by B.anthracis lethal toxin (LT)
CC       endopeptidase promotes ubiquitination and degradation of the N-terminal
CC       part, releasing the cleaved C-terminal part of the protein (NACHT, LRR
CC       and PYD domains-containing protein 1a, C-terminus), which polymerizes
CC       and forms the Nlrp1a inflammasome. {ECO:0000305|PubMed:20502689}.
CC   -!- PTM: [NACHT, LRR and PYD domains-containing protein 1a, N-terminus]:
CC       Ubiquitinated in response to pathogen-associated signals, leading to
CC       its degradation by the proteasome and subsequent release of the cleaved
CC       C-terminal part of the protein (NACHT, LRR and PYD domains-containing
CC       protein 1a, C-terminus), which polymerizes and forms the Nlrp1a
CC       inflammasome. {ECO:0000250|UniProtKB:Q9C000}.
CC   -!- POLYMORPHISM: Nlrp1a gene is extremely polymorphic. 5 alleles have been
CC       described: 1 (this entry), 2 (AC D9I2G3), 3 (AC D9I2H0), 4 (AC D9I2G1)
CC       and 5 (AC D9I2G4). {ECO:0000269|PubMed:20502689}.
CC   -!- SIMILARITY: Belongs to the NLRP family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AABR07029887; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AABR07029888; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AABR07029889; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC095695; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; HM060628; ADI96225.1; -; mRNA.
DR   EMBL; HM060629; ADI96226.1; -; mRNA.
DR   EMBL; HM060631; ADI96228.1; -; mRNA.
DR   EMBL; HM060634; ADI96231.1; -; mRNA.
DR   EMBL; HM060637; ADI96234.1; -; mRNA.
DR   RefSeq; NP_001139227.2; NM_001145755.2.
DR   RefSeq; XP_006246817.1; XM_006246755.3.
DR   PDB; 7CRV; X-ray; 2.00 A; A/C=783-968, B/D=969-1122.
DR   PDB; 7CRW; EM; 3.18 A; A/B=1-1218.
DR   PDBsum; 7CRV; -.
DR   PDBsum; 7CRW; -.
DR   AlphaFoldDB; D9I2F9; -.
DR   SMR; D9I2F9; -.
DR   STRING; 10116.ENSRNOP00000034130; -.
DR   iPTMnet; D9I2F9; -.
DR   PhosphoSitePlus; D9I2F9; -.
DR   PaxDb; 10116-ENSRNOP00000034130; -.
DR   PeptideAtlas; D9I2F9; -.
DR   GeneID; 360557; -.
DR   KEGG; rno:360557; -.
DR   UCSC; RGD:1310963; rat.
DR   AGR; RGD:1310963; -.
DR   CTD; 195046; -.
DR   RGD; 1310963; Nlrp1a.
DR   VEuPathDB; HostDB:ENSRNOG00000023143; -.
DR   eggNOG; ENOG502S4A4; Eukaryota.
DR   InParanoid; D9I2F9; -.
DR   OrthoDB; 338452at2759; -.
DR   TreeFam; TF340267; -.
DR   Reactome; R-RNO-844455; The NLRP1 inflammasome.
DR   Proteomes; UP000002494; Chromosome 10.
DR   ExpressionAtlas; D9I2F9; baseline and differential.
DR   GO; GO:0061702; C:canonical inflammasome complex; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0072558; C:NLRP1 inflammasome complex; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0032991; C:protein-containing complex; IDA:RGD.
DR   GO; GO:0005524; F:ATP binding; ISO:RGD.
DR   GO; GO:0016887; F:ATP hydrolysis activity; ISO:RGD.
DR   GO; GO:0140608; F:cysteine-type endopeptidase activator activity; ISS:UniProtKB.
DR   GO; GO:0003690; F:double-stranded DNA binding; ISO:RGD.
DR   GO; GO:0003725; F:double-stranded RNA binding; ISO:RGD.
DR   GO; GO:0019899; F:enzyme binding; ISO:RGD.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; ISO:RGD.
DR   GO; GO:0038187; F:pattern recognition receptor activity; ISO:RGD.
DR   GO; GO:0008233; F:peptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0019904; F:protein domain specific binding; ISO:RGD.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:RGD.
DR   GO; GO:0035591; F:signaling adaptor activity; ISO:RGD.
DR   GO; GO:0140374; P:antiviral innate immune response; ISO:RGD.
DR   GO; GO:0071493; P:cellular response to UV-B; ISO:RGD.
DR   GO; GO:0042742; P:defense response to bacterium; ISO:RGD.
DR   GO; GO:0051607; P:defense response to virus; ISO:RGD.
DR   GO; GO:0051245; P:negative regulation of cellular defense response; IMP:RGD.
DR   GO; GO:0051402; P:neuron apoptotic process; ISO:RGD.
DR   GO; GO:1904784; P:NLRP1 inflammasome complex assembly; ISO:RGD.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; ISO:RGD.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; ISO:RGD.
DR   GO; GO:0140639; P:positive regulation of pyroptotic inflammatory response; IMP:RGD.
DR   GO; GO:0097300; P:programmed necrotic cell death; ISO:RGD.
DR   GO; GO:0051260; P:protein homooligomerization; ISS:UniProtKB.
DR   GO; GO:0070269; P:pyroptotic inflammatory response; ISO:RGD.
DR   GO; GO:0042981; P:regulation of apoptotic process; IEA:InterPro.
DR   GO; GO:0050727; P:regulation of inflammatory response; ISO:RGD.
DR   GO; GO:0032495; P:response to muramyl dipeptide; ISO:RGD.
DR   GO; GO:0097264; P:self proteolysis; ISO:RGD.
DR   GO; GO:0007165; P:signal transduction; ISO:RGD.
DR   CDD; cd08330; CARD_ASC_NALP1; 1.
DR   Gene3D; 1.10.533.10; Death Domain, Fas; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1.
DR   InterPro; IPR001315; CARD.
DR   InterPro; IPR033516; CARD8/ASC/NALP1_CARD.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR025307; FIIND_dom.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR007111; NACHT_NTPase.
DR   InterPro; IPR041267; NLRP_HD2.
DR   InterPro; IPR051249; NLRP_Inflammasome.
DR   InterPro; IPR041075; NOD1/2_WH.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR46985; NACHT, LRR AND PYD DOMAINS-CONTAINING PROTEIN 1; 1.
DR   PANTHER; PTHR46985:SF3; NACHT, LRR AND PYD DOMAINS-CONTAINING PROTEIN 1; 1.
DR   Pfam; PF00619; CARD; 1.
DR   Pfam; PF13553; FIIND; 1.
DR   Pfam; PF13516; LRR_6; 2.
DR   Pfam; PF05729; NACHT; 1.
DR   Pfam; PF17776; NLRC4_HD2; 1.
DR   Pfam; PF17779; NOD2_WH; 1.
DR   PRINTS; PR00364; DISEASERSIST.
DR   SMART; SM00368; LRR_RI; 3.
DR   SUPFAM; SSF47986; DEATH domain; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   SUPFAM; SSF52047; RNI-like; 1.
DR   PROSITE; PS50209; CARD; 1.
DR   PROSITE; PS51830; FIIND; 1.
DR   PROSITE; PS50837; NACHT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cytoplasm; Hydrolase; Immunity; Inflammasome;
KW   Inflammatory response; Innate immunity; Leucine-rich repeat; Necrosis;
KW   Nucleotide-binding; Nucleus; Protease; Reference proteome; Repeat;
KW   Ubl conjugation.
FT   CHAIN           1..1218
FT                   /note="NACHT, LRR and PYD domains-containing protein 1a
FT                   allele 1"
FT                   /id="PRO_0000452878"
FT   CHAIN           1..968
FT                   /note="NACHT, LRR and PYD domains-containing protein 1a, N-
FT                   terminus"
FT                   /evidence="ECO:0000250|UniProtKB:Q9C000"
FT                   /id="PRO_0000452879"
FT   CHAIN           969..1218
FT                   /note="NACHT, LRR and PYD domains-containing protein 1a, C-
FT                   terminus"
FT                   /evidence="ECO:0000250|UniProtKB:Q9C000"
FT                   /id="PRO_0000452880"
FT   DOMAIN          175..484
FT                   /note="NACHT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00136"
FT   REPEAT          343..364
FT                   /note="LRR 1"
FT                   /evidence="ECO:0000255"
FT   REPEAT          673..693
FT                   /note="LRR 2"
FT                   /evidence="ECO:0000255"
FT   REPEAT          730..750
FT                   /note="LRR 3"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          835..1118
FT                   /note="FIIND"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01174"
FT   DOMAIN          1122..1211
FT                   /note="CARD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00046"
FT   REGION          1..61
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          799..842
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          835..968
FT                   /note="ZU5"
FT                   /evidence="ECO:0000250|UniProtKB:Q9C000"
FT   REGION          969..1118
FT                   /note="UPA"
FT                   /evidence="ECO:0000250|UniProtKB:Q9C000"
FT   COMPBIAS        8..27
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        28..43
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        799..825
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         181..188
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00136"
FT   SITE            942
FT                   /note="Trigger for autolytic processing"
FT                   /evidence="ECO:0000269|PubMed:33731929"
FT   SITE            968..969
FT                   /note="Cleavage; by autolysis"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01174,
FT                   ECO:0000269|PubMed:33731929"
FT   MUTAGEN         942
FT                   /note="H->E: Complete loss of autocatalytic processing."
FT                   /evidence="ECO:0000269|PubMed:33731929"
FT   MUTAGEN         969
FT                   /note="S->A: Abolished autolytic processing."
FT                   /evidence="ECO:0000269|PubMed:33731929"
FT   HELIX           831..833
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          835..837
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          840..842
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          845..848
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   TURN            849..852
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          853..858
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          860..865
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   TURN            867..869
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          872..877
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          879..886
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   HELIX           888..890
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   HELIX           898..900
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          901..903
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          907..911
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          916..923
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   HELIX           935..937
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          938..944
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          947..951
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          954..956
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          958..965
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          970..976
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   TURN            979..983
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          989..998
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          1001..1011
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   HELIX           1013..1024
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   TURN            1025..1027
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          1029..1031
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          1045..1049
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          1054..1057
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          1059..1062
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          1075..1080
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          1086..1092
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   TURN            1093..1095
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   STRAND          1098..1104
FT                   /evidence="ECO:0007829|PDB:7CRV"
FT   HELIX           1106..1108
FT                   /evidence="ECO:0007829|PDB:7CRV"
SQ   SEQUENCE   1218 AA;  138392 MW;  A2C22118B6194DF9 CRC64;
     MEESQSKQES NTRVAQHGSQ QDVDPTFQTK RALEKERSKP RPRPLPRVQL QSLPGWSSTS
     NDVPLSQLIR EMDHESRRCI HRSKKKLDRS EHISQGTIPE IYEKRKETIS HTQSMEQKYL
     FQNFTKLLLL QKCCPGGSEK LVRESWHPCV PEEGGHMIEI QDLFDPNLDT EKKPQLVIIE
     GAAGIGKSTL ARQVKRAWDE GQLYRDRFQH VFFFSCRELA QCKQLSLAEL IAQGQEVPTA
     PTRQILSRPE KLLFILDGID EPAWVLEDQN PELCVHWSQA QPVHTLLGSL LGKSILPEAS
     LMLTARTTAL QKLVPSLGQP HRVEVLGFSE FERKDYFYKY FAKERNTIID FNLIGSIPVL
     LTLCEVPWVC WLLCTCLEKQ MQQGEVLSLT SQTTTALCLK YLSLTIPGQH LSTQLRTLCS
     LAAEGICQRR TLFSKSDLCK QGLAEDAIAT FLKIGVLQRQ PSSLSYSFAH LCLQEFFAAM
     SYILEDSEEA HGDMGNDRTV ETLVERYGRQ NLFEAPTVRF LLGLLNTREM REMENIFACK
     FPWETKLKLL QSIIGEPFCQ PCHLGLFHCL YENQEEELLT ETMLCFPLTA SGPNHMEATV
     FQTNVKRLVI QTDMELMVVT FCITFSHVRS LRLKGKGQQE YKLTAPAMVL YRWTPISEAS
     WKVLFSNLKC TRNLEELDLS GNPLSYSAVR SLCTALRQPG CRLKTLWLVD CGLTSRCCSF
     LASMLSAHSR LAELDLRLND LGDNGVRQLC EGLRNPACNL SILRLDQASL SEQVITELRA
     LETKNPKLFI SSTWMSHMTM PTENTDGEES LTSSKQQQQQ SGDKHMEPLG TDDDFWGPSG
     PVSTEVVDRE RNLYRVRLPM AGSYHCPSTG LHFVVTRAVT IEIGFCAWSQ FLHETPLQHS
     HMVAGPLFDI KAEHGAVTAV CLPHFVSLQE GKVDSSLFHV AHFQDHGMVL ETPARVEPHF
     AVLENPSFSP MGVLLRMIPA VGHFIPITSI TLIYYRLYLE DITFHLYLVP NDCTIRKAID
     EEELKFQFVR INKPPPVDAL YVGSRYIVSS SKEVEILPKE LELCYRSPRE SQLFSEIYVG
     NIGSGINLQL TDKKYMNLIW EALLKPGDLR PALPRMASAP KDAPALLHFV DQHREQLVAR
     VTSVDPLLDK LHGLVLSEED YETVRAEATN QDKMRKLFRG SRSWSWDCKD HFYQALKETH
     PHLIMDLLEK SGGVSVRL
//
